Successful Launch of GRAFAPEX
GRAFAPEX exceeded prelaunch expectations with the strongest month of patient demand in October 2025. $6.2 million in net revenue was recognized in the first six months, and it is expected to positively contribute to quarterly operating cash flows by fiscal Q3 2026.
Positive Reimbursement Developments
Starting October 1, 2025, eligible procedures under Medicare using GRAFAPEX are eligible for additional reimbursement through the NTAP program, facilitating adoption.
Gross Margin Improvement
Gross margin for fiscal Q2 2026 was 55.7%, an improvement from 53.7% in the same period last year.
Cost Reduction in IXINITY Manufacturing
IXINITY's manufacturing process improvement initiative resulted in a 30% decrease in product level cost of goods since fiscal Q1 2021.